Ireland
--:--IST
Recruiting Not applicable

Efficacy and Adverse Side Effects of Two Forms of Iron in Pregnancy

NCT06014983 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2024-04-12
Last updated
2026-04-24

Condition(s) studied

PregnancyIron Deficiency

Investigational drug(s) / intervention(s)

Ferrous fumarateFerrous bisglycinate

Ferrous fumarate: Participants will supplement with 24 mg elemental iron in the form of ferrous fumarate daily for a minimum of 12 weeks.

Ferrous bisglycinate: Participants will supplement with 24 mg elemental iron in the form of ferrous bisglycinate daily for a minimum of 12 weeks.

Study summary

This two-arm, double-blind randomized clinical trial will recruit 172 generally healthy, low-risk pregnant individuals aged 19-42 years living in Vancouver, Canada. Participants will be randomized to receive one of two forms of iron (ferrous fumarate or ferrous bisglycinate) in addition to a prenatal multivitamin (without iron) daily during their pregnancy until delivery, with optional continuation until \~4 weeks postpartum for breastmilk sample collection. Blood samples will be taken at baseline (13-25 weeks gestation) and follow-up (35-37 weeks gestation) to assess how different forms of iron impact body iron stores. Stool samples will be obtained within 1 week of both baseline and follow-up visits to assess changes in gut microbiome composition. This research will inform more specific guidelines for optimal iron supplementation practices for the prevention and treatment of iron deficiency for both mother and baby.

Eligibility

Sex
FEMALE
Min age
19 Years
Max age
42 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Pregnant individual (singleton pregnancy) * 19-42 years of age * Living in the greater Vancouver area and willing to travel to the University of British Columbia or BC Women's Hospital for study visits * 13-25 weeks gestation * Willing to participate and able to provide informed consent Exclusion Criteria: * Having a pre-existing medical condition known to impact iron status (e.g., inherited hemoglobin disorder (i.e., sickle cell, hemochromatosis, thalassemia or other structural hemoglobin variant), malabsorptive disorders (i.e., chronic pancreatitis, cystic fibrosis, celiac disease) and inflammatory bowel disease (i.e., Crohn's disease, ulcerative colitis), gastric bypass surgery, atrophic gastritis, advanced liver disease, kidney dialysis) * Using medications known to interfere with iron metabolism or the gut pathogen equilibrium (e.g., chronic use of proton pump inhibitors, anti-inflammatory agents, non-steroidal anti-inflammatory drugs, antibiotics) * Having a personal neural tube defect (NTD) history or a previous NTD pregnancy * Receiving ongoing blood transfusions * Currently smoking or having smoked in the past 3 months * Pre-pregnancy body mass index (BMI) ≥30 kg/m\^2 * Allergy to any study supplement ingredients

Primary outcome measure(s)

  • Maternal ferritin concentration — Blood sample collected at baseline (13-25 weeks gestation) and at follow-up (35-37 weeks gestation)
    µg/L; reflects body iron stores

Trial sites (2)

FacilityCityRegionStatus
BC Women's Hospital Vancouver British Columbia Recruiting
University of British Columbia, Food, Nutrition and Health Building Vancouver British Columbia Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06014983 on ClinicalTrials.gov ↗ ← All trials in Canada